跳至主要内容
临床试验/NCT04408443
NCT04408443终止不适用

Evaluation of a Food Supplement Containing Lactobacillus Reuteri DSM 17938 + Vitamin D3 in the Prevention of Recurrent Respiratory Infections in Paediatric Patients

Noos S.r.l.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2019年11月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
发起方
入组人数
200
试验地点
1
主要终点
Change of the number of respiratory infection

研究概览

简要总结

The aim of this protocol is to evaluate, in a multicenter, randomized, double blind vs placebo clinical trial the effects of a marketed food supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 (Reuterin® D3) in the prevention of recurrent respiratory infections in pediatric patients suffered from Recurrent Respiratory Infection (RRI) in previous years.

详细描述

Several clinical trials documented the efficacy of probiotics in the prevention and treatment of acute gastroenteritis, while there is little evidence on the efficacy of the probiotics in the prevention of children respiratory infections.

The biological activity of probiotics is linked, partly, to their capacity to adhere to enterocytes. This would avoid the binding of pathogenic bacteria through a competitive exclusion mechanism. This inhibition toward pathogen bacteria on epithelial and mucosal level (substrate), thanks also to the production of antimicrobial substances, can have a beneficial effect on the balance of the intestinal microflora of the host and improve its immunity.

The adhesion of probiotic bacteria to the enterocyte membrane receptors influences the activation of second messengers that induces the production of cytokines. The presence of probiotic bacteria influences the commensal microorganisms in the production of lactic acid and bacteriocins. These substances inhibit the growth of pathogens and modify the balance of commensal bacteria of the intestinal bacterial flora.

Numerous controlled clinical trials show that L. reuteri DSM 17938 colonizes the human gastric and intestinal epithelium and modulates the immune response, particularly through CD4 + T-helper cells in the ileum. These data confirm the pre-clinical evidence obtained in animal models; furthermore these immunomodulatory effects may explain some clinical properties of L. reuteri DSM 17938 such as the prevention of diarrhea, inhibition of pathogen infectionand the following immune system response of the host to these pathogens, as well as the potential modulation of the immune response by the Th1/Th2 balance in the human intestinal epithelium, an answer that has been linked to the prevention and treatment of allergy. In a recent, randomized, double-blind, placebo-controlled clinical trial, L. reuteri DSM 17938, supplemented for three months to healthy children aged 6-36 months attending nursery schools, demonstrated not only a significant reduction of episodes and duration of diarrhea but also of respiratory tract infections with consequent reduction of costs for society.

Despite the prevalence of food with vitamin D and multivitamin products, reports regarding non-optimal vitamin D levels in adults and children in the world have increased, in particular among those subjects overweight and with dark pigmentation of the skin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
1 Year 至 6 Years(Child)
性别
All
接受健康志愿者
是

入选标准

  • •Patients between 1 and 6 years of age at the enrollment; both sexes
  • •Patients with an history of RRI, according to the definition (The definition of Recurrent respiratory infections (RRI) is the onset of 8 or more documented airway infections during the year, in preschool children (up to three years of age) or 6 or more in children older 3 years, in the absence of any other underlying pathological condition) in the previous year.
  • •Atopic and non-atopic patients
  • •Willing and able to give informed consent of participation in the study by parent or legal guardian.

排除标准

  • •Presence of autoimmune diseases, immunodeficiency, neuromuscular diseases, congenital cardiomyopathies, metabolic diseases
  • •Patients in therapy with other drugs for the treatment of RRI
  • •Supplementation with probiotics and /or prebiotics in the previous 2 weeks
  • •Vitamin D intake in the last 4 weeks
  • •IgA deficiency
  • •Antibiotic treatment at least 4 week before in inclusion
  • •Participation in other clinical trials

研究组 & 干预措施

Reuterin D3

Active Comparator

Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.

干预措施: Lactobacillus reuteri DSM 17938 + Vitamine D3 (Dietary Supplement)

Placebo

Placebo Comparator

Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Change of the number of respiratory infection

时间窗: 4 months + 2 months of follow up

Change of the number of respiratory infection respect the previous year

次要结局

  • Change of number of days with fever(4 months + 2 months of follow up)
  • Change of number of visit to Pediatrician(4 months + 2 months of follow up)
  • Change of the antibiotic use(4 months + 2 months of follow up)
  • Modification of intestinal microflora(4 months + 2 months of follow up)
  • Change of number of days of absence from the nursery / kindergarten(4 months + 2 months of follow up)
  • Changes of days of absence from work by parents(4 months + 2 months of follow up)

研究者

发起方
Noos S.r.l.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验